Has the time come for induction and main
β
Edgar Faber
π
Article
π
2009
π
Elsevier Science
π
English
β 90 KB
Imatinib has revolutionized the treatment of chronic myeloid leukemia (CML) and there is no doubt about its role in the first-line therapy of this myeloproliferation. However, there is continuing discussion about how to dose it. Routinely, avoiding single doses lower than 300 mg and continuous daily